Cyriac Roeding is the CEO of Earli, a gene therapy company aiming to make cancer a manageable condition by forcing tumors to express synthetic, non-human biomarkers for early detection.
A successful founder and investor, Cyriac previously served as CEO of Shopkick, acquired for $250M, and has invested in breakthrough companies like OpenAI. He’s known for building ventures at the intersection of the physical and digital worlds. Now leading Earli, he’s raised nearly $60M from top-tier investors to advance the company’s mission and redefine how cancer is detected and treated.
